Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Nephrol ; 25(1): 188, 2024 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-38831308

RESUMO

BACKGROUND: Long-term enzyme replacement therapy (ERT) may improve prognosis in the patients with Fabry disease (FD), however, detail psychosocial burden has not been focused on long life expectancy. We experienced a male case of FD under ERT, he was placed on hemodialysis and presented rapidly progressive cognitive function. CASE PRESENTATION: A 51-year-old male patient with FD has been receiving ERT from age of 38 years. Hemodialysis was initiated at the age of 47 years. The patient experienced several attacks of cerebral infarction, and brain images demonstrated wide-spread asymptomatic ischemic lesions. His behavior became problematic at the age of 51 years. He often exhibited restlessness during hemodialysis sessions and failure to communicate effectively. The patient experienced impairment of attention and executive function, topographical disorientation, and amnesia. Consequently, it was necessary for medical staff and family members to monitor his behavior for safe extracorporeal circulation and daily life activities. Annual standardized neuropsychiatric testing revealed worsening of cognitive performance. CONCLUSIONS: Despite treating with long-term ERT, it is necessary to determine the psychosocial burden derived from the progression of cognitive impairment in patients with FD undergoing hemodialysis.


Assuntos
Disfunção Cognitiva , Terapia de Reposição de Enzimas , Doença de Fabry , Diálise Renal , Humanos , Masculino , Doença de Fabry/psicologia , Doença de Fabry/complicações , Diálise Renal/psicologia , Pessoa de Meia-Idade , Disfunção Cognitiva/etiologia , Disfunção Cognitiva/psicologia , Progressão da Doença , Efeitos Psicossociais da Doença
2.
Sci Rep ; 11(1): 22126, 2021 11 11.
Artigo em Inglês | MEDLINE | ID: mdl-34764337

RESUMO

(-)-Carvone is a monoterpenoid with a spearmint flavor. A sustainable biotechnological production process for (-)-carvone is desirable. Although all enzymes in (-)-carvone biosynthesis have been functionally expressed in Escherichia coli independently, the yield was low in previous studies. When cytochrome P450 limonene-6-hydroxylase (P450)/cytochrome P450 reductase (CPR) and carveol dehydrogenase (CDH) were expressed in a single strain, by-product formation (dihydrocarveol and dihydrocarvone) was detected. We hypothesized that P450 and CDH expression levels differ in E. coli. Thus, two strains independently expressing P450/CPR and CDH were mixed with different ratios, confirming increased carvone production and decreased by-product formation when CDH input was reduced. The optimum ratio of enzyme expression to maximize (-)-carvone production was determined using the proteome analysis quantification concatamer (QconCAT) method. Thereafter, a single strain expressing both P450/CPR and CDH was constructed to imitate the optimum expression ratio. The upgraded strain showed a 15-fold improvement compared to the initial strain, showing a 44 ± 6.3 mg/L (-)-carvone production from 100 mg/L (-)-limonene. Our study showed the usefulness of the QconCAT proteome analysis method for strain development in the industrial biotechnology field.


Assuntos
Monoterpenos Cicloexânicos/metabolismo , Escherichia coli/metabolismo , Limoneno/metabolismo , Proteoma/metabolismo , Oxirredutases do Álcool/metabolismo , Sistema Enzimático do Citocromo P-450/metabolismo , Monoterpenos/metabolismo , NADPH-Ferri-Hemoproteína Redutase/metabolismo , Proteínas de Plantas/metabolismo
3.
J Biosci Bioeng ; 121(2): 172-7, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26168906

RESUMO

Phosphoenolpyruvate carboxylase (PEPC) in Corynebacterium glutamicum ATCC13032, a glutamic-acid producing actinobacterium, is subject to feedback inhibition by metabolic intermediates such as aspartic acid and 2-oxoglutaric acid, which implies the importance of PEPC in replenishing oxaloacetic acid into the TCA cycle. Here, we investigated the effects of feedback-insensitive PEPC on glutamic acid production. A single amino-acid substitution in PEPC, D299N, was found to relieve the feedback control by aspartic acid, but not by 2-oxoglutaric acid. A simple mutant, strain R1, having the D299N substitution in PEPC was constructed from ATCC 13032 using the double-crossover chromosome replacement technique. Strain R1 produced glutamic acid at a concentration of 31.0 g/L from 100 g/L glucose in a jar fermentor culture under biotin-limited conditions, which was significantly higher than that of the parent, 26.0 g/L (1.19-fold), indicative of the positive effect of desensitized PEPC on glutamic acid production. Another mutant, strain DR1, having both desensitized PEPC and PYK-gene deleted mutations, was constructed in a similar manner using strain D1 with a PYK-gene deleted mutation as the parent. This mutation had been shown to enhance glutamic acid production in our previous study. Although marginal, strain D1 produced higher glutamic acid, 28.8 g/L, than ATCC13032 (1.11-fold). In contrast, glutamic acid production by strain DR-1 was elevated up to 36.9 g/L, which was 1.42-fold higher than ATCC13032 and significantly higher than the other three strains. The results showed a synergistic effect of these two mutations on glutamic acid production in C. glutamicum.


Assuntos
Corynebacterium glutamicum/metabolismo , Ácido Glutâmico/biossíntese , Fosfoenolpiruvato Carboxilase/metabolismo , Ácido Aspártico/metabolismo , Ácido Aspártico/farmacologia , Reatores Biológicos , Biotina/metabolismo , Ciclo do Ácido Cítrico , Corynebacterium glutamicum/enzimologia , Retroalimentação Fisiológica , Glucose/metabolismo , Ácido Glutâmico/metabolismo , Ácidos Cetoglutáricos/metabolismo , Ácidos Cetoglutáricos/farmacologia , Fosfoenolpiruvato Carboxilase/química , Fosfoenolpiruvato Carboxilase/genética , Piruvato Quinase/deficiência , Piruvato Quinase/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...